Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia.

[1]  R. Kusec,et al.  Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. , 2018, Leukemia research.

[2]  K. Döhner,et al.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. , 2017, Leukemia research.

[3]  F. Lussana,et al.  Inflammation and myeloproliferative neoplasms. , 2017, Journal of autoimmunity.

[4]  S. Verstovsek,et al.  JAK2 inhibitors for myeloproliferative neoplasms: what is next? , 2017, Blood.

[5]  K. Döhner,et al.  Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group , 2016, Haematologica.

[6]  H. Yin,et al.  Hepcidin: A Promising Therapeutic Target for Iron Disorders , 2016, Medicine.

[7]  G. Birgegard,et al.  A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial , 2016, Pharmacotherapy.

[8]  F. Cervantes,et al.  Alleviating anemia and thrombocytopenia in myelofibrosis patients , 2016, Expert review of hematology.

[9]  T. Barbui,et al.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both , 2016, Leukemia.

[10]  F. Cervantes,et al.  Long-term results of prednisone treatment for the anemia of myelofibrosis , 2016, Leukemia & lymphoma.

[11]  H. Hasselbalch,et al.  MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives , 2015, Mediators of inflammation.

[12]  Arturo Pereira,et al.  Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results , 2015, Annals of Hematology.

[13]  G. Birgegard,et al.  Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy , 2014, Medical Oncology.

[14]  K. Döhner,et al.  Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. , 2014, Blood.

[15]  G. Birgegard.  Does anything work for anaemia in myelofibrosis? , 2014, Best practice & research. Clinical haematology.

[16]  B. Favrat,et al.  Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women – PREFER a Randomized, Placebo-Controlled Study , 2014, PloS one.

[17]  S. Verstovsek,et al.  Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. , 2014, Clinical therapeutics.

[18]  A. Tefferi,et al.  Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis , 2013, American journal of hematology.

[19]  A. Tefferi,et al.  Associations and Prognostic Interactions Between Circulating Levels of Hepcidin, Ferritin, and Inflammatory Cytokines in Primary Myelofibrosis. , 2012 .

[20]  T. Barbui,et al.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. , 2011, Blood.

[21]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[22]  G. Birgegard,et al.  The role of iron supplementation during epoietin treatment for cancer-related anemia , 2009, Medical oncology.

[23]  E. Nemeth.  Iron regulation and erythropoiesis , 2008, Current opinion in hematology.

[24]  G. Birgegard,et al.  Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study , 2008, Leukemia.

[25]  G. Birgegard,et al.  Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study , 2007, Leukemia.

[26]  N. Andrews,et al.  Anemia of inflammation: the hepcidin link , 2005, Current opinion in hematology.